Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) reached a new 52-week high on Thursday . The stock traded as high as $11.25 and last traded at $11.25, with a volume of 1,449,433 shares changing hands. The stock had previously closed at $10.90.

Separately, Maxim Group reissued a “hold” rating on shares of SciClone Pharmaceuticals in a report on Thursday, June 8th.

The firm’s 50 day moving average is $10.93 and its 200-day moving average is $10.11. The stock has a market capitalization of $582.64 million, a price-to-earnings ratio of 15.85 and a beta of 1.71.

In related news, CEO Friedhelm Blobel sold 70,000 shares of SciClone Pharmaceuticals stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $10.91, for a total value of $763,700.00. Following the completion of the sale, the chief executive officer now owns 152,209 shares of the company’s stock, valued at approximately $1,660,600.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of SciClone Pharmaceuticals stock in a transaction on Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the completion of the sale, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last ninety days, insiders sold 253,726 shares of company stock valued at $2,662,024. 5.16% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. LS Investment Advisors LLC raised its stake in SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 8,355 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,320 shares during the last quarter. State of Alaska Department of Revenue raised its stake in SciClone Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 4,503 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 310 shares during the last quarter. Finally, Mason Street Advisors LLC raised its stake in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 881 shares during the last quarter. 71.92% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/03/sciclone-pharmaceuticals-inc-scln-hits-new-1-year-high-at-11-25.html.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.